Adding a GLP-1 agonist to other diabetes drugs reduces the risk of major adverse cardiovascular events (MACE) and all-cause mortality, a population-based study suggests.

The Danish observational study also concludes that the use of sulfonylureas as second-line therapy to metformin is not supported, say the researchers, from Aalborg University.

The researchers compared the eight most frequently used therapies or combinations of therapies added to metformin.

Using two decades of data for nearly 67,000 Danes with type 2 diabetes, the most-common combination regimen was metformin with a sulfonylurea — used by nearly 25,000 people.